左炔诺孕酮宫内释放系统对子宫腺肌病治疗价值评析.docVIP

左炔诺孕酮宫内释放系统对子宫腺肌病治疗价值评析 　　[摘要] 目的 评估左炔诺孕酮宫内释放系统在子宫腺肌病治疗中的临床价值。方法 方便选取2013年2月―2016年11月该院100例子宫腺肌病患者，按照随机数字法分组，分析对照组50例常规治疗与实验组50例左炔诺孕酮宫内释放系统治疗的患者的不良反应发生率、治疗总有效率、性激素指标、临床指标、痛经积分。 结果 两组不良反应发生率、性激素指标差异无统计学意义（P0.05）；实验组治疗总有效率较96.00%高于对照组（P0.05），痛经积分（6.35±1.42）分少于对照组（P0.05），血清CA125（24.3±5.2）kU/L、月经量PBAC评分（45.21±17.46）分、子宫体积（95.36+17.64）cm3等临床指标优于对照组，差异有统计学意义（P0.05）。结论 左炔诺孕酮宫内释放系统治疗子宫腺肌病痛经积分低，临床指标能够显著改善，效果确切。 　　[关键词] 子宫腺肌病；左炔诺孕酮宫内释放系统；临床价值 　　[中图分类号] R711 [文献标识码] A [文章编号] 1674-0742（2017）05（b）-0135-03 　　[Abstract] Objective To evaluate the clinical value of levonorgestrel-releasing intrauterine system in treatment of adenomyosis. Methods 100 cases of adenomyosis patients treated in our hospital from February 2013 to November 2016 were convenient selected and randomly divided into two groups with 50 cases in each， the control group adopted the routine treatment， while the experimental group adopted the levonorgestrel-releasing intrauterine system treatment， and the incidence rate of adverse reactions， total treatment effective rate， sexy hormone index， clinical index and dysmenorrhea scores were compared between the two groups. Results The differences in the incidence rate of adverse reactions and sexy hormone between the two groups were not statistically significant（P0.05）， and the total effective rate in the experimental group was 96.00%， which was higher than that in the control group（P0.05）， and the dysmenorrhea score was （6.35±1.42）points， which was fewer than that in the control group（P0.05）， and the serum CA125， menstrual flow PBAC score and uterus volume in the experimental group were respectively（24.3±5.2）kU/L， （45.21±17.46）points and （95.36±17.64）cm3， which were better than those in the control group， and the differences between groups were statistically significant（P0.05）. Conclusion The dysmenorrhea score of levonorgestrel-releasing intrauterine system in treatment of adenomyosis is low， which can obviously improve the clinical indexes and the effect is defin